# US 2024/0197855 A1 · Foot-and-mouth disease vaccine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197855 A1
- Document ID: US20240197855A1
- Status: Published application
- Kind: A1
- Application number: 18/511,123
- Filed: 2023-11-16
- Published: 2024-06-20
- Earliest claimed: 2015-01-16
- Assignees: Zoetis Services LLC; The United States of America as represented by the Secretary of Agriculture
- Applicants: Zoetis Services LLC; United States of America, as Represented by the Secretary of Agriculture
- Inventors: Paul Joseph Dominowski; John Morgan Hardham; James Alan Jackson; Cyril Gerard Gay; Luis Leandro Rodriguez; Peter William Krug; Aida Elizabeth Rieder
- Web page: https://patentgrep.com/patent/US20240197855A1

## CPC

- A61K 39/135: Foot- and mouth-disease virus
- A61K 39/12: Viral antigens
- A61K 39/39: characterised by the immunostimulating additives, e.g. chemical adjuvants
- A61P 31/12: Antivirals
- A61P 31/14: for RNA viruses
- A61P 37/04: Immunostimulants
- A61K 2039/5252: {inactivated (killed)}
- A61K 2039/552: {Veterinary vaccine}
- A61K 2039/555: {characterised by a specific combination antigen/adjuvant}
- A61K 2039/55505: {Inorganic adjuvants}
- A61K 2039/55511: {Organic adjuvants}
- A61K 2039/55561: {CpG containing adjuvants; Oligonucleotide containing adjuvants}
- A61K 2039/55566: {Emulsions, e.g. Freund's adjuvant, MF59}
- A61K 2039/55583: {Polysaccharides}
- C12N 2770/32034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2770/32134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Compositions for prevention of Foot and Mouth Disease (FMD) are provided, comprising an antigen component in the amount equivalent to 0.5-20 μg FMD virus and an adjuvant component comprising oil, an immunostimulatory oligonucleotide, and a polycationic carrier. Methods of using the composition, as well as the methods of reducing FMD persistence are also provided.

## Claims

### Claim at position 1

1-29. (canceled)

### Claim 30

A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising at least 6 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are not slaughtered and wherein the CpG containing immunostimulatory oligonucleotide comprises a 5′ TLR activation domain and at least two palindromic regions, one palindromic region being a 5′ palindromic region of at least 6 nucleotides in length and connected to a 3′ palindromic region of at least 8 nucleotides in length either directly or through a spacer.

### Claim 31

A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising at least 6 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are quarantined for 0-30 days.

### Claim 32

A method of herd management, comprising administering to each member in said herd an immunogenic composition wherein said immunogenic composition comprises: a) antigen component comprising at least 6 μg of FMD (Foot-and-Mouth Disease) virus per dose; b) an emulsion containing an oil; c) 75-200 μg of a CpG-containing immunostimulatory oligonucleotide per dose; d) 75-200 mg of a polycationic carrier per dose, and wherein further, upon suspected contact with FMD infection, the vaccinated members of said herd are moved beyond the infected premises.

### Claim 33 (depends on 30)

The method according to claim 30, wherein the vaccinated members of the herd are not slaughtered and are quarantined for 0-30 days.

### Claim 34 (depends on 30, 31, 32, 33)

The method according to any one of claim 30-33, wherein the CpG containing immunostimulatory oligonucleotide comprises a 5′ TLR activation domain and at least two palindromic regions, one palindromic region being a 5′ palindromic region of at least 6 nucleotides in length and connected to a 3′ palindromic region of at least 8 nucleotides in length either directly or through a spacer.

### Claim 35 (depends on 34)

The method according to claim 34, wherein CpG containing immunostimulatory oligonucleotide comprises at least one of:
a) an iodo-modified nucleotide;
b) one or more phosphorothioate bonds.

### Claim 36 (depends on 35)

The method according to claim 35, wherein the iodo-modified nucleotide is the 5′-nucleotide of said CpG containing immunostimulatory oligonucleotide.

### Claim 37 (depends on 36)

The method according to claim 36, wherein the immunostimulatory oligonucleotide comprises one or more phosphorothioate bonds and an iodo-modified nucleotide.

### Claim 38 (depends on 37)

The method according to claim 37, wherein the polycationic polymer is diethylaminoethyl (DEAE) Dextran.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the oil is a light mineral oil.

### Claim 40 (depends on 39)

The method according to claim 39, wherein oily phase comprises 50.01%-55% v/v of the immunogenic composition.

### Claim 41 (depends on 40)

The method of claim 40, wherein said immunogenic composition comprises 6-20 μg of FMD (Foot-and-Mouth Disease) virus per dose.

### Claim 42 (depends on 40)

The method of claim 40, wherein said immunogenic composition comprises 6-18 μg of FMD (Foot-and-Mouth Disease) virus per dose.

### Claim 43 (depends on 40)

The method of claim 40, wherein said immunogenic composition comprises 8-12 μg of FMD (Foot-and-Mouth Disease) virus per dose.
